Dapeng Zhou

Title: Dapeng Zhou: Innovator in Cancer Therapeutics

Introduction

Dapeng Zhou is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of cancer therapeutics through his innovative research and development of monoclonal antibodies.

Latest Patents

Dapeng Zhou holds a patent for "Monoclonal and humanized antibodies to a cancer glycopeptide." This invention discloses a mouse-human chimeric antibody that specifically recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells. The patent includes the encoding sequences for the monoclonal antibody, which consists of a light chain and a heavy chain. Furthermore, the invention provides humanized light and heavy chains along with their encoding sequences. The results of paired expression demonstrate that the humanized antibodies also recognize the MUC1 glycopeptide epitope with the same specificity as the parental antibody.

Career Highlights

Throughout his career, Dapeng Zhou has worked with notable organizations, including Nanocruise Pharmaceutical Ltd. and the University of Texas System. His work has focused on advancing cancer treatment options through innovative antibody development.

Collaborations

Dapeng Zhou has collaborated with various professionals in his field, including Patrick Hwu, to enhance the impact of his research and innovations.

Conclusion

Dapeng Zhou's contributions to cancer therapeutics through his patented inventions highlight his role as a key innovator in the field. His work continues to pave the way for advancements in cancer treatment.